Total Payments
$2,398
2024 Payments
$874.85
Companies
32
Transactions
79
Medicare Patients
9,821
Medicare Billing
$3.0M
Payment Breakdown by Category
Food & Beverage$2,354 (98.2%)
Education$43.94 (1.8%)
Other$0.00 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $2,354 | 76 | 98.2% |
| Education | $43.94 | 3 | 1.8% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Janssen Scientific Affairs, LLC | $227.60 | 4 | $0 (2023) |
| AstraZeneca Pharmaceuticals LP | $201.52 | 8 | $0 (2024) |
| Celgene Corporation | $191.43 | 5 | $0 (2024) |
| Novartis Pharmaceuticals Corporation | $158.73 | 10 | $0 (2024) |
| Merck Sharp & Dohme LLC | $157.97 | 3 | $0 (2024) |
| Bayer HealthCare Pharmaceuticals Inc. | $157.12 | 2 | $0 (2019) |
| Incyte Corporation | $141.24 | 2 | $0 (2024) |
| Takeda Pharmaceuticals U.S.A., Inc. | $119.34 | 2 | $0 (2024) |
| Seattle Genetics, Inc. | $106.92 | 1 | $0 (2018) |
| CTI BioPharma Corp. | $105.86 | 1 | $0 (2022) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $874.85 | 44 | AstraZeneca Pharmaceuticals LP ($188.47) |
| 2023 | $397.86 | 10 | Janssen Scientific Affairs, LLC ($212.25) |
| 2022 | $260.18 | 8 | CTI BioPharma Corp. ($105.86) |
| 2021 | $136.92 | 2 | Celgene Corporation ($125.00) |
| 2020 | $116.46 | 1 | Merck Sharp & Dohme Corporation ($116.46) |
| 2019 | $292.50 | 6 | Incyte Corporation ($125.00) |
| 2018 | $319.54 | 8 | Seattle Genetics, Inc. ($106.92) |
All Payment Transactions
79 individual payment records from CMS Open Payments — Page 1 of 4
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/13/2024 | AstraZeneca Pharmaceuticals LP | IMFINZI (Biological) | Food and Beverage | In-kind items and services | $25.00 | General |
| Category: Oncology | ||||||
| 12/08/2024 | Merck Sharp & Dohme LLC | WELIREG (Drug) | Education | In-kind items and services | $18.09 | General |
| Category: ONCOLOGY | ||||||
| 12/05/2024 | Janssen Biotech, Inc. | DARZALEX (Biological), TALVEY, TECVAYLI | Food and Beverage | In-kind items and services | $20.50 | General |
| Category: Oncology | ||||||
| 12/03/2024 | Lilly USA, LLC | VERZENIO (Drug), RETEVMO, JAYPIRCA | Food and Beverage | In-kind items and services | $23.18 | General |
| Category: Oncology | ||||||
| 11/19/2024 | Mirati Therapeutics, Inc. | KRAZATI (Drug) | Food and Beverage | Cash or cash equivalent | $22.39 | General |
| Category: Oncology | ||||||
| 11/19/2024 | Novartis Pharmaceuticals Corporation | KISQALI (Drug) | Food and Beverage | In-kind items and services | $19.56 | General |
| Category: Oncology | ||||||
| 11/07/2024 | AstraZeneca Pharmaceuticals LP | IMFINZI (Biological) | Food and Beverage | In-kind items and services | $30.98 | General |
| Category: Oncology | ||||||
| 11/06/2024 | Novartis Pharmaceuticals Corporation | SCEMBLIX (Drug) | Food and Beverage | In-kind items and services | $15.58 | General |
| Category: Oncology | ||||||
| 11/05/2024 | PFIZER INC. | INLYTA (Drug), PADCEV | Food and Beverage | In-kind items and services | $27.79 | General |
| Category: ONCOLOGY | ||||||
| 10/31/2024 | Takeda Pharmaceuticals U.S.A., Inc. | ICLUSIG (Drug) | Food and Beverage | In-kind items and services | $29.83 | General |
| Category: ONCOLOGY | ||||||
| 10/29/2024 | Exelixis Inc. | CABOMETYX (Drug) | Food and Beverage | In-kind items and services | $13.61 | General |
| Category: Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid Cancer (DTC) | ||||||
| 10/21/2024 | Janssen Biotech, Inc. | ERLEADA (Drug) | Food and Beverage | In-kind items and services | $17.12 | General |
| Category: Oncology | ||||||
| 10/16/2024 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological), REBLOZYL, WELIREG | Food and Beverage | In-kind items and services | $23.42 | General |
| Category: ONCOLOGY | ||||||
| 10/15/2024 | Celgene Corporation | REBLOZYL (Biological) | Food and Beverage | Cash or cash equivalent | $19.91 | General |
| Category: Hematology | ||||||
| 10/10/2024 | Novartis Pharmaceuticals Corporation | Fabhalta (Drug) | Food and Beverage | In-kind items and services | $24.33 | General |
| Category: Immunology | ||||||
| 10/10/2024 | Novartis Pharmaceuticals Corporation | SCEMBLIX (Drug) | Food and Beverage | In-kind items and services | $6.65 | General |
| Category: Oncology | ||||||
| 10/08/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $18.23 | General |
| 10/01/2024 | AstraZeneca Pharmaceuticals LP | ENHERTU (Biological) | Food and Beverage | In-kind items and services | $18.17 | General |
| Category: Oncology | ||||||
| 09/29/2024 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Food and Beverage | Cash or cash equivalent | $14.05 | General |
| Category: Oncology | ||||||
| 09/28/2024 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Food and Beverage | Cash or cash equivalent | $14.97 | General |
| Category: Oncology | ||||||
| 08/21/2024 | Incyte Corporation | JAKAFI (Drug) | Food and Beverage | Cash or cash equivalent | $16.24 | General |
| Category: Hematology/Oncology | ||||||
| 08/14/2024 | Celgene Corporation | REBLOZYL (Biological) | Food and Beverage | Cash or cash equivalent | $16.22 | General |
| Category: Hematology | ||||||
| 08/08/2024 | PFIZER INC. | PADCEV (Biological) | Food and Beverage | In-kind items and services | $17.11 | General |
| Category: Oncology | ||||||
| 08/08/2024 | Myriad Genetic Laboratories, Inc. | MYRISK (Device) | Food and Beverage | In-kind items and services | $16.19 | General |
| Category: ONCOLOGY | ||||||
| 07/24/2024 | Novartis Pharmaceuticals Corporation | SCEMBLIX (Drug) | Food and Beverage | In-kind items and services | $14.32 | General |
| Category: Oncology | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 33 | 2,125 | 27,636 | $1.6M | $431,454 |
| 2022 | 30 | 2,164 | 17,817 | $1.5M | $445,850 |
| 2021 | 36 | 2,364 | 51,260 | $1.8M | $489,150 |
| 2020 | 56 | 3,168 | 127,641 | $6.3M | $1.6M |
Total Patients
9,821
Total Services
224,354
Medicare Billing
$3.0M
Procedure Codes
155
All Medicare Procedures & Services
155 procedure records from CMS Medicare Utilization — Page 1 of 7
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| J9271 | Injection, pembrolizumab, 1 mg | Office | 2023 | 13 | 3,801 | $501,486 | $163,236 | 32.6% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 357 | 889 | $236,474 | $85,852 | 36.3% |
| J0897 | Injection, denosumab, 1 mg | Office | 2023 | 21 | 2,820 | $147,542 | $51,978 | 35.2% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 78 | 187 | $67,133 | $25,689 | 38.3% |
| J0881 | Injection, darbepoetin alfa, 1 microgram (non-esrd use) | Office | 2023 | 11 | 10,500 | $255,360 | $24,343 | 9.5% |
| 96413 | Administration of chemotherapy into vein, 1 hour or less | Office | 2023 | 72 | 138 | $65,136 | $14,595 | 22.4% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 175 | 217 | $38,409 | $13,415 | 34.9% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2023 | 402 | 1,582 | $18,984 | $13,267 | 69.9% |
| 85025 | Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | Office | 2023 | 400 | 1,469 | $58,760 | $11,167 | 19.0% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 41 | 41 | $21,033 | $6,817 | 32.4% |
| J0185 | Injection, aprepitant, 1 mg | Office | 2023 | 13 | 3,120 | $25,397 | $4,257 | 16.8% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 23 | 23 | $9,407 | $2,819 | 30.0% |
| 96375 | Injection of additional new drug or substance into vein | Office | 2023 | 53 | 216 | $15,984 | $2,682 | 16.8% |
| 96417 | Administration of additional new drug or substance into vein, 1 hour or less | Office | 2023 | 20 | 43 | $9,976 | $2,236 | 22.4% |
| 96365 | Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | Office | 2023 | 30 | 36 | $8,100 | $1,862 | 23.0% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2023 | 58 | 128 | $9,088 | $1,433 | 15.8% |
| 96415 | Administration of chemotherapy into vein, each additional hour | Office | 2023 | 15 | 52 | $5,460 | $1,179 | 21.6% |
| 96402 | Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | Office | 2023 | 15 | 36 | $4,320 | $982.80 | 22.8% |
| 85027 | Complete blood cell count (red cells, white blood cell, platelets), automated test | Office | 2023 | 40 | 117 | $3,744 | $741.78 | 19.8% |
| 96360 | Infusion into a vein for hydration, 31-60 minutes | Office | 2023 | 21 | 24 | $4,224 | $630.72 | 14.9% |
| 96523 | Irrigation of implanted venous access drug delivery device | Office | 2023 | 19 | 22 | $1,936 | $439.02 | 22.7% |
| 96366 | Infusion into a vein for therapy, prevention, or diagnosis, each additional hour | Office | 2023 | 11 | 24 | $1,656 | $395.10 | 23.9% |
| 96361 | Infusion into a vein for hydration, each additional hour | Office | 2023 | 21 | 32 | $1,696 | $327.95 | 19.3% |
| J2469 | Injection, palonosetron hcl, 25 mcg | Office | 2023 | 22 | 370 | $42,236 | $300.46 | 0.7% |
| 81002 | Urinalysis, manual test | Office | 2023 | 13 | 54 | $648.00 | $184.14 | 28.4% |
About Dr. Maury Blitman, MD
Dr. Maury Blitman, MD is a Hematology & Oncology healthcare provider based in Spokane Valley, Washington. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 03/09/2006. The National Provider Identifier (NPI) number assigned to this provider is 1396713095.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Maury Blitman, MD has received a total of $2,398 in payments from pharmaceutical and medical device companies, with $874.85 received in 2024. These payments were reported across 79 transactions from 32 companies. The most common payment nature is "Food and Beverage" ($2,354).
As a Medicare-enrolled provider, Blitman has provided services to 9,821 Medicare beneficiaries, totaling 224,354 services with total Medicare billing of $3.0M. Data is available for 4 years (2020–2023), covering 155 distinct procedure/service records.
Ad
Practice Information
- Specialty Hematology & Oncology
- Other Specialties Internal Medicine, Hematology & Oncology
- Location Spokane Valley, WA
- Active Since 03/09/2006
- Last Updated 01/15/2020
- Taxonomy Code 207RH0003X
- Entity Type Individual
- NPI Number 1396713095
Products in Payments
- ERLEADA (Drug) $221.56
- REBLOZYL (Biological) $191.43
- Xofigo (Drug) $157.12
- IMFINZI (Biological) $141.81
- JAKAFI (Drug) $141.24
- KEYTRUDA (Biological) $139.88
- EPKINLY (Drug) $115.65
- ADCETRIS (Biological) $106.92
- Vonjo (Drug) $105.86
- NINLARO (Drug) $89.51
- DARZALEX (Biological) $56.14
- KISQALI (Drug) $48.26
- SCEMBLIX (Drug) $46.97
- ENHERTU (Biological) $46.66
- Fabhalta (Drug) $44.57
- OPDIVO (Biological) $44.30
- KRAZATI (Drug) $42.50
- SARCLISA (Biological) $41.28
- CABOMETYX (Drug) $36.61
- IMBRUVICA (Drug) $35.35
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.